Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study
- 576 Downloads
To assess the pattern and probable risk factors for moderate and major drug–drug interactions in a referral hematology–oncology ward in Iran.
All patients admitted to hematology–oncology ward of Dr. Shariati Hospital during a 6-month period and received at least two anti-cancer or non-anti-cancer medications simultaneously were included. All being scheduled anti-cancer and non-anti-cancer medications both prescribed and administered during ward stay were considered for drug–drug interaction screening by Lexi-Interact On-Desktop software.
One hundred and eighty-five drug–drug interactions with moderate or major severity were detected from 83 patients. Most of drug–drug interactions (69.73 %) were classified as pharmacokinetics. Fluconazole (25.95 %) was the most commonly offending medication in drug–drug interactions. Interaction of sulfamethoxazole-trimethoprim with fluconazole was the most common drug–drug interaction (27.27 %). Vincristine with imatinib was the only identified interaction between two anti-cancer agents. The number of administered medications during ward stay was considered as an independent risk factor for developing a drug–drug interaction.
Potential moderate or major drug–drug interactions occur frequently in patients with hematological malignancies or related diseases. Performing larger standard studies are required to assess the real clinical and economical effects of drug–drug interactions on patients with hematological and non-hematological malignancies.
KeywordsDrug–drug interactions Hematology–oncology ward Hematological malignancies Iran
Conflict of interest
The authors declare that they have no competing interests.
- 10.Guédon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L’Hôte C, Deligne J, Caron J (2004) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59:899–904PubMedCrossRefGoogle Scholar
- 13.Lexi-interact. http://webstore.lexi.com/Lexi-Interact. Accessed June 1 2012
- 17.World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2012. http://www.whocc.no/atcddd/index. Accessed 1 June 2012
- 33.Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD (2004) The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther 76:313–322PubMedCrossRefGoogle Scholar
- 41.Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B, European Organization for Research and Treatment of Cancer (EORTC), Leukaemia Cooperative Group (LCG), Dutch Haemato-Oncology Cooperative Study Group (HOVON) (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115:895–902PubMedCrossRefGoogle Scholar